# Angus Grant

> Angus Grant is a startup investor at Dementia Discovery Fund (Boston). See 0 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Dementia Discovery Fund](https://shizune.co/investors/profile/dementia-discovery)
- Location: Boston, United States
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/angus-grant-7228639/

Angus Grant is a startup investor at Dementia Discovery Fund in Boston. Angus Grant joined Celgene as Vice President North American Regulatory Affairs in 2006, in the Summit NJ Headquarters. In 2008, Angus moved to London as Head of Europe RA for 3 years. Angus returned to the Summit NJ Headquarters as VP, Business Development and Global Alliances, in 2011, where he has since completed multiple innovative deals and hasin tandem built the Alliance Management function, which now manages over 50 collaborations and investments with pharmaceutical and biotech partners.Prior to joining Celgene, Angus held positions as Executive Director for Alliance Management for Novartis Oncology, and positions of increasing responsibility in Regulatory Affairs for Merck KGaA/EMD, Rhone-Poulenc Rorer, and SmithKline Beecham Pharmaceuticals. Prior to working in industry, Angus served as a Senior Staff Fellow at the U.S. Food and Drug Administration Center for Biologics, and conducted his post-doctoral research in immunotherapy at the National Cancer Institute. Angus received his Ph.D. in Anatomy & Immunology from the Medical College of Virginia.

## About Dementia Discovery Fund

VC Fund · London, United Kingdom

The Dementia Discovery Fund is the world’s largest venture fund focused entirely on discovering and developing novel therapies for dementia, including Alzheimer’s disease.The DDF has raised a total of £250 million to develop novel disease-modifying therapeutics for all forms of dementia.They have a mandate to validate novel hypotheses andexpand the breadth of targets and mechanisms in development for dementia over the 15 year life of the fund.This enables the DDF to invest in truly novel, early-stage projects starting from target identification, and explore novel biological insights for translation into disease-modifying drugs.

5 contacts available at Dementia Discovery Fund.

| Name | Title | Profile |
| --- | --- | --- |
| Angus Grant | Chief Executive Officer | https://shizune.co/investors/profile/angus-grant |
| Barbara Tate | Chief Strategy Officer | https://shizune.co/investors/profile/barbara-tate |
| Jonathan Behr | Partner | https://shizune.co/investors/profile/jonathan-behr-2 |
| Jonathan Behr | Partner | https://shizune.co/investors/profile/jonathan-behr-1cb6 |
| Damian Crowther | Entrepreneur In Residence | https://shizune.co/investors/profile/damian-crowther |

## FAQ

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co